STAT+: The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences
There’s really no ignoring the inexorable math that led the Senate to approve a plan…
Category: drug pricing
In a massive victory for Democrats, Medicare is poised to negotiate drug prices
WASHINGTON — President Biden is on the verge of his own crowning health care achievement…
Democrats dramatically narrow their ambitions for lowering insulin costs
WASHINGTON — Democrats’ high hopes to lower insulin costs for patients with insurance got downsized on…
.jpg)
Democrats will have to limit their drug pricing reforms to Medicare to comply with Senate rules
WASHINGTON — Democrats will likely have to axe two provisions from their drug pricing plan…
The glaring health equity gap in Democrats’ drug pricing plan
WASHINGTON — As Democrats close in on the biggest overhaul of the Medicare prescription drug…
Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble
Is drug pricing reform really happening this time? Are things finally turning around for biotech?…
Opinion: Are ‘modest’ drug price controls as bad for innovation as pharma claims?
Drug price controls proposed by Democrats in the U.S. Senate are being met with dire…
STAT+: Lilly is ordered to pay $61 million for shortchanging the Medicaid drug rebate program
After nearly a decade of legal squabbling, Eli Lilly was ordered by a federal court…
STAT+: Civica Rx begins selling its first generic drug as it tries to overhaul the pharmaceutical supply chain
In the latest bid to address high prescription drug costs, a nonprofit plans to sell…
Opinion: WTO: Don’t make a bad situation worse by granting intellectual property waivers for Covid-19 therapeutics and diagnostics
The World Trade Organization recently agreed to suspend patent protections for Covid-19 vaccines. The trade…
The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital
In an embarrassing episode for AbbVie, the company was reprimanded by a U.K. pharmaceutical industry…
STAT+: Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices
In his ongoing quest to probe pharmaceutical industry tax practices, the head of the U.S….
STAT+: ‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing
WASHINGTON — The pharmaceutical industry, notorious for its deep pockets and aggressive lobbying tactics, has a…
STAT+: Pfizer loses another court battle alleging the U.S. illegally limits use of copay assistance programs
In another setback for the pharmaceutical industry, a federal appeals court panel upheld a ruling…
Opinion: Drug price controls are a dance with the devil: short-term savings will be overwhelmed by loss of innovation
Democrats have sent the legislative text of a sweeping proposal for drug price controls to…
Powerful Senate Democrat outlines ‘plenty’ more drug pricing reforms to follow Medicare negotiation
WASHINGTON — Democrats may be closer than ever to passing sweeping drug pricing reforms, but…
Virtual Event: Democrats’ Last Chance for Drug Pricing Reform?
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
PhRMA and BIO descend on D.C. & unpacking the Senate’s FDA funding drama
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: The politics of passing a major FDA funding bill just got complicated
WASHINGTON — For the last six months, Congress seemed to be sailing towards the uncharacteristically…
STAT+: Dozens of lawmakers urge HHS to fine drugmakers for curtailing discounts to a federal program
Dozens of lawmakers are demanding the Biden administration penalize drug companies that have curtailed discounts…
.jpg)
STAT+: Federal patent initiatives could cause ‘headwinds’ for drugmakers and their broad filings
For the second time this month, the U.S. Patent & Trademark Office has taken a…
Biden tells Dems to quickly pass pared-down economic package
WASHINGTON (AP) — President Joe Biden seemed to bow Friday to Sen. Joe Manchin’s demand…
Opinion: STAT+: Value-based drug pricing: When does it work best?
Value-based drug pricing offers an important way to bring down the high cost of drugs…
Opinion: Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need
America’s economically disadvantaged patients can point in two directions when talking about what is wrong…
STAT+: Here’s what Democrats changed in their latest drug pricing bill
WASHINGTON — Senate Democrats have put final tweaks on their drug pricing proposal, as they…
Democrats tweak their drug pricing plan in last-ditch effort to pass reforms
WASHINGTON — Senate Democrats are vetting a new, tweaked version of a drug pricing package as…
The unlikely crusader who’s winning the fight to lower hospital prices
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Opinion: PBMs are inflating the cost of generic drugs. They must be reined in
These are not comfortable days in Washington for pharmacy benefit managers, the highly consolidated group…
STAT+: 100 lawmakers ask HHS to use controversial federal laws to combat high drug prices
A group of 100 federal lawmakers is urging the Biden administration to use controversial provisions…
STAT+: A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs
Three years ago, a former CVS Health executive told a U.S. Senate committee hearing that…
STAT+: Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Industry-funded studies on cost-effectiveness often favor pricier drugs, study finds
In response to rising prices for medicines, public and private payers increasingly rely on assessments…
STAT+: Pharmalittle: Medicare could have saved billions if it paid what Cuban charges; India’s drug controller accused of taking bribe
Top of the morning to you, and a fine one it is. The sun is…
STAT+: Medicare could have saved billions on drugs if it paid what Mark Cuban charges at his new pharmacy
Amid growing anger over the cost of medicines, a new analysis finds that Medicare could…
STAT+: European Commission investigates Vifor for ‘disparaging’ its only rival in iron deficiency market
The European Commission has opened an investigation into allegations that Vifor Pharma spread misleading information…
STAT+: Lawmakers ask GAO to probe pharmacy benefit managers over their role in drug pricing
Amid intensifying scrutiny of pharmacy benefit managers, a group of House Republicans is urging the…
Opinion: Reformulating drugs helps profits more than patients
Prescription drug prices remain stubbornly high in the U.S. even though making drugs more affordable…
STAT+: FTC puts drugmakers and PBMs on notice that it will crack down on illegal rebate schemes
In a notable move, the Federal Trade Commission put drugmakers and pharmacy benefit managers on…
STAT+: A ‘veritable playground’: CVS whistleblower details how patients were charged higher drug prices
The conversation reflected frustration and disbelief. A woman had called SilverScript, which runs one of…
STAT+: Supreme Court sides with hospitals on Medicare drug pay dispute
WASHINGTON — The Supreme Court on Wednesday sided with hospitals in a legal dispute over…
The Senate health committee finally marks up its user fee bill
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: A widely anticipated ALS drug wouldn’t be cost effective if priced the same as an older rival
Amid growing demand for ALS treatments, a preliminary analysis finds an experimental medicine that may…
STAT+: Klobuchar, Porter call for FTC to investigate price hikes by Janssen, Bristol Myers Squibb
WASHINGTON — Two prominent Democratic lawmakers are requesting that the Federal Trade Commission investigate whether…
Opinion: Pursuit of profits is driving drug companies to break the 340B law
Seventeen drug companies, including some of the world’s largest, are flouting a 30-year-old federal program…
STAT+: How high? Prices for newly launched medicines rose 20% annually, analysis finds
Talk about inflation Amid ongoing angst over prescription drug costs, a new analysis finds that…
STAT+: FTC will investigate pharmacy benefit managers and their role in prescription drug costs
After months of deliberation, the U.S. Federal Trade Commission has voted unanimously to investigate several…
STAT+: ‘All about strengthening health systems’: New coalition pushes to license cancer drugs to low-income countries
Over the past two decades, public health officials and patient advocacy groups have pushed the…
STAT+: Italian authorities fine drugmaker for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in Italy have fined a drugmaker nearly $3.8 million for years of “excessive”…